Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk @RheumNow #EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N

• EULAR Abstract Archive

Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B

• EULAR Abstract Archive

Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to general population. No significant risk for AV block (II-III). Unclear if treatment affects cardiac risk in these patients. @RheumNow #EULAR2022 ABST#POST0146

COVID-19 mostly mild for majority of SpA patients. Steroid use associated with more severe COVID-19 outcomes (OR 3.15). TNFi found to be protective! (OR 0.26) @RheumNow #EULAR2022 ABST#OP0254

Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=1.06 [1.04-1.08]) while anti-TNF (OR=0.26 [0.09-0.78]) was protective @RheumNow #EULAR2022 OP0254 https://t.co/bIiEW6efQ2

• EULAR Abstract Archive

#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH

Ok to taper? In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering. 69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months. Taper group did use more NSAIDs, cDMARDs, steroids @RheumNow #EULAR2022 ABST#OP0261

Pregnancy data in SpA from 122 pts 40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz 7 pts required start of TNFi during 2nd or 3rd trimester 40% post-partum @RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH

SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn

The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

#OP0248 #EULAR2022 In contrast to data from #OP0247 where SpA was protective, a matched population study in Canada found the opposite - increased risk of hospitalisation & death in SpA. A meta-analysis cd help to disentangle this @RheumNow https://t.co/keNZ2RPnXF

WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022 https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH

• https://bit.ly/3MbzRcJ